Our data suggest that together with the demonstrated oncogenic roles performed by ERRα and ERG, combined evaluation of co-expressions of ERRα and ERG may provide a better prognosis for prostate cancer or predictor of sensitivity to hormone therapy. The gene discussed is ESRRA; the disease is Familial prostate cancer.